- Home
- About
- Section Advisors
- Meet Our Field Medical Affairs Team
- Speakers Bureau
- Supporting Organizations
- Contact Us
- PsychU For You
- Topics
- Mental Health Disorders
- Agitation
- Bipolar Disorder
- Depression
- PTSD/Trauma
- Schizophrenia
- Substance Use Disorders
- Topics of Interest
- Care Coordination
- Digital Health
- Diversity, Equity, & Inclusion
- Health Care Policy, Quality & Payer Administration
- Long-Term Care
- Stigma
- Suicide Awareness
- Wellness
- Events
- Content
- Infographics
- Learning Tracks
- Podcasts
- Shareable/Downloadable Content
- Videos
- PsychUSim
- PsychU Roleplay
- Frameworks In Health & Quality Resources
- Mental Health System Guidebooks
- Psychiatric Scales
- Psychopharmacology
- Supporting Organizations
Virtual Event – Trace Amine-Associated Receptor 1 (TAAR1): A Potential New Target For The Treatment Of Schizophrenia
Thank You For Attending Today’s Webinar
Please tell us what you thought about today’s presentation by taking the survey below:
About This Event
Virtual Event – Trace Amine-Associated Receptor 1 (TAAR1): A Potential New Target For The Treatment Of Schizophrenia
This is a Virtual Live Event for PsychU Members in Alaska, Oregon, and Washington.
Trace amines and trace amine-associated receptors (TAAR) are found throughout the brain and peripheral tissues and have modulating effects on neurotransmitters including dopamine, glutamate, and serotonin. The speakers will discuss what are some of the potential effects of TAAR1 on neurotransmitter signaling related to schizophrenia and some of the preclinical data, as well as share the potential role of TAAR1 beyond schizophrenia.
Objectives:
- Summarize the Unmet Needs of Schizophrenia as it Relates to Neural Circuitry
- Introduction to Trace Amines (TA) and Trace Amine-Associated Receptors (TAARs) and Their Potential Relationship to Schizophrenia
- Discuss Potential Modulating Effects of TAAR1 on Neurotransmitter Signaling Associated with Schizophrenia Pathophysiology
Featuring
Chet Robachinski, MD
Psychiatric Director, Bailey-Boushay House, Seattle, WA; Founding Partner, Associates in Behavioral Health
Simon Kim, PharmD (OPDC)
Medical Science Liaison
Speaker Chet Robachinski, MD is a paid consultant for Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC)
Speaker Simon Kim, PharmD is an employee of Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC)Related Events
Registration
Related Resources
-
Practical Application of Wellness Strategies for Individuals in Underserved Communities with Major Depressive Disorder (MDD) & Post-Traumatic Stress Disorder (PTSD)
On-Demand Webinar July 12, 2024Approximately 50 million United States adults are living with a mental illness, with 21 million having depression and 13 million with post-traumatic stress disorder.1-4 Minority individuals are among these prevalence…
-
Talking Points (Part I): Primary Care on PTSD – David Lewis
Podcast July 10, 2024Listen to Amica Simmons-Yon, PharmD, PhD as she spills the tea on a new Talking Points Series from Primary Care on Post-Traumatic Stress Disorder (PTSD) with special guest, David E….
-
Primary Care PTSD Screen For DSM-5 (PC-PTSD-5)
Downloadable Resource June 27, 2024The Primary Care PTSD Screen for DSM-5 (PC-PTSD-5) is a 5-item screen designed to identify individuals with probable PTSD in primary care settings. The measure begins with an item which assesses lifetime…
Join today for instant access to all PsychU content, events, and more!
Membership is free!
"*" indicates required fields
Join PsychU Today to receive a wide array of tools and benefits
- Join our multidisciplinary community that is improving mental health care… together
- Quickly learn more about the topics you're interested in
- Access an award-winning library of on-demand mental health resources
- Gain key insights from industry expert & thought leaders
Stay Connected: